ASH Leukemia Review: the more we learn, the less we know!

ASH Leukemia Review: the more we learn, the less we know!

From WolverHeme Happy Hour by Bernard Marini, Anthony Perissinotti, et al.

December 17, 2025 · 1h 23m · Season 1 · Episode 43

About this episode

The episode discusses significant ASH abstracts in leukemia with insights from Dr. Justin Kaner.

In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts should change practice? Listen to find out. Some of the abstracts discussed: PARADIGM: https://meetings-api.hematology.org/api/abstract/vmpreview/296881 KMT2A Outcomes (MARROW Consortium and Othman, et al.): https://meetings-api.hematology.org/api/abstract/vmpreview/302582 and https://meetings-api.hematology.org/api/abstract/vmpreview/297333 CLIA +/- Ven: https://meetings-api.hematology.org/api/abstract/vmpreview/302047 FLT3i studies (and MRD): https://meetings-api.hematology.org/api/abstract/vmpreview/295719 and https://meetings-api.hematology.org/api/abstract/vmpreview/302699 and https://meetings-api.hematology.org/api/abstract/vmpreview/291322 ALL GIMEMA Trial (blin + ponatinib): https://meetings-api.hematology.org/api/abstract/vmpreview/296532 Menin inhibitor data

People in this episode

Hosts: Anthony Perissinotti, Bernard Marini

Guest: Dr. Justin Kaner

Topics covered

  • leukemia
  • ASH abstracts
  • medical research
  • oncology
  • clinical trials

Keywords

  • leukemia
  • ASH 2025
  • clinical trials
  • PARADIGM
  • FLT3i studies

Mentioned in this episode

Organizations: Weill Cornell Medicine

Books & works: PARADIGM, KMT2A Outcomes, CLIA +/- Ven, FLT3i studies, ALL GIMEMA Trial, Menin inhibitor data

More episodes of WolverHeme Happy Hour

Explore listener stats, chart rankings, contacts and more on the WolverHeme Happy Hour podcast page.